The extension, released shortly before the flexibilities were set to expire at the end of 2025, gives regulators more time to ...
The Drug Enforcement Administration (DEA) published a yearlong extension of telemedicine prescribing flexibilities for ...
The Drug Enforcement Administration (DEA) has finalized quotas for legal production of controlled substances in 2026—further ...
The American Telemedicine Association announced that the U.S. Drug Enforcement Administration, or DEA, granted a 1-year ...
DEA extends telemedicine prescribing flexibilities through 2026, allowing remote controlled substance prescriptions without in-person visits.
The extension allows providers to continue remotely prescribing Schedule II–V controlled substances under specific conditions ...
DEA finalizes one-year extension of telehealth prescribing, punts final regs to incoming Trump admin
The Drug Enforcement Administration (DEA) will extend pandemic-era telehealth prescribing flexibilities for one year, through Dec. 31, 2025, according to an unpublished rule that hit the Federal ...
EXTON, Pa., Sept. 24, 2025 /PRNewswire/ -- ProRx Pharma, the leading health and wellness 503B outsourcing facility, announced today it has been awarded a DEA Controlled Substances Registration ...
The U.S. Drug Enforcement Administration has proposed draft guidance to establish a framework for prescribing controlled substances via telemedicine. The proposal introduces three types of special ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback